Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATRA 
Atara Biotherapeutics Inc (ATRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: ATRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.33
1 Year Target Price $16.33
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.86% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 102.39M USD | Price to earnings Ratio 4.95 | 1Y Target Price 16.33 |
Price to earnings Ratio 4.95 | 1Y Target Price 16.33 | ||
Volume (30-day avg) 5 | Beta -0.4 | 52 Weeks Range 5.00 - 18.70 | Updated Date 12/5/2025 |
52 Weeks Range 5.00 - 18.70 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.87 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.26 | Actual -0.32 |
Profitability
Profit Margin 15.4% | Operating Margin (TTM) -102.72% |
Management Effectiveness
Return on Assets (TTM) 30.86% | Return on Equity (TTM) -2014.86% |
Valuation
Trailing PE 4.95 | Forward PE 166.67 | Enterprise Value 93409988 | Price to Sales(TTM) 0.67 |
Enterprise Value 93409988 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA 3.06 | Shares Outstanding 7210235 | Shares Floating 4151509 |
Shares Outstanding 7210235 | Shares Floating 4151509 | ||
Percent Insiders 20.58 | Percent Institutions 45.73 |
Upturn AI SWOT
Atara Biotherapeutics Inc
Company Overview
History and Background
Atara Biotherapeutics, Inc. was founded in 2012. The company focuses on developing allogeneic T-cell immunotherapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Key milestones include the development of tab-celu00ae and ATA188.
Core Business Areas
- Allogeneic T-cell Immunotherapies: Developing off-the-shelf T-cell immunotherapies using allogeneic (donor-derived) T cells to target specific antigens associated with diseases.
- Solid Tumors: Developing immunotherapies targeting solid tumors. These immunotherapies are designed to activate the body's own immune system to recognize and destroy cancer cells.
- Hematologic Cancers: Researching and developing immunotherapies for hematologic cancers. These therapies aim to provide patients with alternative treatment options.
- Autoimmune Diseases: Developing targeted treatments for autoimmune conditions, aiming to modulate the immune response and reduce disease severity.
Leadership and Structure
Pascal Touchon is the President and Chief Executive Officer. The company has a management team responsible for research and development, clinical operations, and commercial strategy. The Board of Directors oversees corporate governance and strategy.
Top Products and Market Share
Key Offerings
- Tab-celu00ae (Tabelecleucel): An allogeneic T-cell immunotherapy targeting Epstein-Barr virus (EBV)-positive cancers. Currently, it is approved for certain EBV-positive post-transplant lymphoproliferative disease (PTLD) in Europe and other countries. Competitors: Kite Pharma, Adaptimmune.
- ATA188: An allogeneic T-cell immunotherapy targeting Epstein-Barr virus (EBV) associated with multiple sclerosis (MS). It is currently in Phase 2 clinical trials. Competitors: Biogen, Roche, Novartis.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth driven by advancements in T-cell therapies, checkpoint inhibitors, and CAR-T cell therapies. The industry is characterized by intense competition, high R&D spending, and regulatory scrutiny.
Positioning
Atara Biotherapeutics is positioned as a leader in allogeneic T-cell immunotherapy, leveraging its Allo-T platform. The company's competitive advantage lies in its ability to develop off-the-shelf therapies that can be readily available to patients.
Total Addressable Market (TAM)
The total addressable market (TAM) for cell therapies is estimated to reach billions of dollars. Atara Biotherapeutics' focus on EBV-associated diseases and autoimmune conditions positions it to capture a significant share of this market. The MS TAM is also projected to be a multibillion dollar market.
Upturn SWOT Analysis
Strengths
- Proprietary Allo-T platform for developing allogeneic T-cell immunotherapies
- Focus on EBV-associated diseases and autoimmune conditions
- Positive clinical trial results for tab-celu00ae and ATA188
- Experienced management team with expertise in cell therapy development
- European approval of tab-celu00ae provides a revenue stream
Weaknesses
- High R&D expenses
- Dependence on clinical trial outcomes
- Regulatory hurdles for approval in key markets
- Limited commercial infrastructure
- Risk of manufacturing challenges associated with cell therapies
Opportunities
- Expanding tab-celu00ae to other EBV-positive indications
- Advancing ATA188 through clinical development for MS
- Partnering with larger pharmaceutical companies for commercialization
- Developing new allogeneic T-cell therapies for other diseases
- Potential for breakthroughs in autoimmune disease treatment.
Threats
- Competition from other cell therapy companies
- Failure of clinical trials
- Changes in regulatory landscape
- Pricing and reimbursement pressures
- Adverse events associated with cell therapies
Competitors and Market Share
Key Competitors
- GILD
- BMY
- NVS
Competitive Landscape
Atara faces competition from established pharmaceutical companies and specialized cell therapy firms. Advantages include its Allo-T platform and focus on EBV-associated diseases. Disadvantages include limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by clinical development and regulatory milestones rather than revenue generation.
Future Projections: Future growth depends on the successful development and commercialization of ATA188 for MS and expanded use of Tab-cel. Analyst estimates vary based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include focusing resources on key clinical programs, seeking partnerships, and managing cash burn.
Summary
Atara Biotherapeutics is a biotech company focused on allogeneic T-cell therapies. The company has experienced regulatory success with Tab-celu00ae in Europe, but faces challenges in its clinical development pipeline, specifically ATA188. High R&D costs and reliance on clinical trial outcomes are significant risks. Strategic partnerships are essential for achieving long-term sustainability and growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, SEC filings, company website, publicly available industry reports, analyst reports.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atara Biotherapeutics Inc
Exchange NASDAQ | Headquaters Thousand Oaks, CA, United States | ||
IPO Launch date 2014-10-16 | President, CEO & Director Dr. Anhco Nguyen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.atarabio.com |
Full time employees 38 | Website https://www.atarabio.com | ||
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.